The real drug development delay? Bad communication.
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for ...
VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of 2026, ...
Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener Moleculin Biotech ( ...
Purple Biotech Ltd. announced it is advancing NT219, a novel drug aimed at overcoming tumor resistance to therapy, into a Phase 2 clinical trial for patients with recurrent/metastatic squamous cell ...
Cervical cancer causes approximately 350,000 global annual deaths, with 94% occurring in low- and middle-income countries. Despite decades of progress in women’s health screening, key gaps in cervical ...
SAN DIEGO and CALGARY, AB, Feb. 19, 2025 /PRNewswire/ — Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to ...
Recent breakthroughs in dental biotechnology are pushing the boundaries of regenerative dentistry, from a keratin-based enamel repair toothpaste to antibody drugs that may regrow teeth by 2030.
The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global regulations. Considering the advancements, fundamentally solid biotech stocks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results